Thromboembolic Disorders: Discontinue Caprogen® if an arterial or deep venous thrombotic or thromboembolic event occurs.
Allergic Reactions: Allergic reactions, including urticaria, pruritusand angioedema, have been reported with use of Caprogen® or with other products containing
castor oil. Consider discontinuing the drug if such reactions occur.
Decrease in Glucose Tolerance: A decrease in glucose tolerance has been observed in some patients on progestin treatment. The mechanism of this decrease is not known. Carefully monitor pre-diabetic and diabetic women while they are receiving Caprogen®.
Fluid Retention: Because progestational drugs may cause some degree of fluid retention, carefully monitor women with conditions that might be influenced by this effect (e.g., preeclampsia, epilepsy, migraine, asthma, cardiac or renal dysfunction).
Depression: Monitor women who have a history of clinical depression and discontinue Caprogen® if clinical depression recurs.
Jaundice: Carefully monitor women who develop jaundice while receiving Caprogen® and consider whether the benefit of use warrants continuation.
Hypertension: Carefully monitor women who develop hypertension while receiving Caprogen® and consider whether the benefit of use warrants continuation.